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Objective 
The aim of the study was to determine risk factors associated with graft failure and mortality after 
transplantation of the intestine alone or as part of an organ complex. 
Summary Background Data 
Even with modem immunosuppressive therapies, clinical intestinal transplantation remains a 
difficult and unreliable procedure. Causes for this and solutions are needed. 
Methods 
Between May 1990 and February 1995, 71 intestinal transplantations were performed in H6 
patients using tacrolimus and low-dose steroids, The first 63 patients, all but one treated 1 to 5 
years ago, received either isolated grafts (n = 22), liver and intestinal grafts (n = 30), or 
multivisceral grafts (n = 11). Three more recipients of allografts who recently underwent surgery 
and one undergoing retransplantation were given unaltered donor bone marrow cells 
perioperatively as a biologic adjuvant. 
Results 
Of the first 63 recipients, 32 are alive: 28 have functioning primary grafts and 4 have resumed total 
parenteral nutrition after graft enterectomy. Thirty-five primary grafts were lost to technical and 
management errors (n = 10), rejection (n = 6), and infection (n = 19). Regression analysis 
revealed that duration of surgery, positive donor cytomegalovirus (CMV) serology, inclusion of 
graft colon, OKT3 use, steroid recycle, and high tacrolimus blood levels contributed to graft loss. 
All four intestine and bone marrow reCipients are alive for 2-3 months without evidence of graft-
versus-host disease. 
Conclusion 
To improve outcome after intestinal transplantation with previous management protocols. it will be 
necessary to avoid predictably difficult patients, CMV seropositive donors, and inclusion of the 
graft colon. Bone marrow transplantation may further improve outcome by ameliorating the 
biologic barriers of rejection and infection and allowing less restrictive selection criteria. 
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Two problems were predicted with intestinal trans-
plantation for which simultaneous resolution was not 
easily envisioned. By analogy with bone marrow trans-
plantation1.2 or with direct experimentation,3-6 it ap-
peared that either the recipient would reject a histoin-
compatible intestine or the immunocytes in the leuko-
cyte-laden bowel would gain ascendency and reject the 
host (graft-versus-host disease [GVHD]). Recent labora-
tory and clinical research with intestinal transplanta-
tion7-10 played a critical role in overthrowing this false 
dogma and in establishing a generic two-way (bidirec-
tional) paradigm of transplantation immunology that is 
relevant to all organs. 11,12 The reassessment began in No-
vember 1987, when a 3-year-old multivisceral recipient 
developed neither rejection nor GVHD, 13 
In this first example of a functioning human intesti-
nal allograft, the cadaveric organs were depleted of T 
lymphocytes by infusing the donor with OKT3 treat-
ment before procurement and by ex vivo irradiation af-
ter their removal. The graft conditioning was suspected 
to have contributed to the widespread B-celllymphoma 
that caused death more than 6 months later,9,13 During 
the subsequent 2 years, four more patients achieved 
prolonged function of cadaveric intestine grafts, trans-
planted alone '4 or as a component ofliver-intestineI5,16 
or multivisceral allografts. 17 Only the intestine-alone 
recipient of Goulet et al. I4 is still alive, but the two liver-
intestine recipients of Grant et al. and McAlister et 
al. 15,16 survived for 58 and 66 months. Additionally, a 
60-cm living donor jejunoileal segment transplanted by 
DeItz et aL 18 to an adult in February 1988 supported 
nutrition for 61 months and was the first successful iso-
lated intestinal transplantation in the world. Cyclospor-
ine-based immunosuppression was used in all of these 
cases. 
In 1989, the advent of the new immunosuppressant 
FK 506 (tacrolimus [Prograf, Fujisawa Pharmaceuti-
cal Co., Osaka, Japan]) allowed more consistent sur-
vival of rae' 19-21 and human intestinal and multivis-
ceral recipients. 1O,22-24 We report here the first 66 pa-
tients treated with this drug, all but the last 4 with 
follow-ups of 1 to 5 years. The last three patients and 
an additional one undergoing intestinal retransplanta-
tion also were given unaltered adjuvant donor bone 
marrow. 
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Table 1. CAUSES OF INTESTINAL FAILURE 
Children 
Cause 
Volvulus 
Gastroschisis 
Necrotizing enterocolitis 
Intestinal atresia 
Pseudo-obstruction 
Microvillus inclusion disease 
Intestinal polyposis 
Hirschsprung's disease 
Total 
METHODS 
Case Material 
Adults 
No. Cause 
9 Thrombotic disorder 
8 Chron's disease 
6 Desmoid tumor 
6 Intestinal trauma 
3 Intestinal adhesions 
3 Pseudo-obstruction 
Malignant gastrinoma 
Volvulus 
37 Total 
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No. 
8 
7 
5 
4 
2 
29 
Under immunosuppression with tacrolimus and low-
dose steroids, 71 intestinal transplantations were per-
formed in 66 patients between May 1990 and February 
1995, There were 37 children, 16 male and 21 female, 
with a mean age of 4.3 ± 4.2 years. Twenty-nine were 
patients were adults, 16 male and 13 female, with a mean 
age of 33.3 ± 9,5 years, The original diseases ultimately 
leading to transplantation are listed in Table 1. Two 
adults had extensive thrombosis of the mesenteric ve-
nous system, creating the most difficult technical prob-
lems in our experience. Two other adults with this con-
dition died of massive hemorrhage while the incision was 
made for preliminary dissection of the native organs; 
they were excluded from the analysis. 
All but three of the recipients had been managed by 
total parenteral nutrition (TPN) for a mean duration of 
36 ± 35 months. They had experienced multiple epi-
sodes of TPN-related complications, such as line sepsis, 
major vessel thrombosis, cholelithiasis, renal stones, and 
hepatic dysfunction. Sixty-two patients (94%) had un-
dergone an average of 3.1 previous laparotomies, and 13 
patients had a history of more than 5 previous opera-
tions. Of the 54 patients with short-bowel syndrome, 
only 5 retained the large bowel including the ileocecal 
valve. The average length of the remaining proximal 
small bowel was 14 ± 13 cm in children and 26 ± 23 cm 
in adults. 
All of the patients were followed until April 6, 1995, 
Median follow-up was 21 months, ranging from 1.5 
months to 57 months. Because of a moratorium 
throughout most of 1994, all but four of the patients have 
had follow-up of at least 1 year (range, 1 to 5 years). 
Donors 
The grafts were obtained from ABO blood type identi-
cal cadaveric donors, Lymphocytotoxic cross-match was 
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n=32 
n = 11 
positive in seven patients. Matching of human leukocyte 
antigen (HLA) was random and poor. Donor manage-
ment and operative procedures have been described else-
where.9,25,26 The University of Wisconsin solution was 
used for organ preservation in all but one case. Cold isch-
emia time from aortic clamping until graft revasculari-
zation averaged 7.7 ± 2.4 hours. 
Transplantation Operations 
The three kinds of allografts are shown in Figure 1: 
isolated intestinal (n = 23), combined intestine and liver 
(n = 32), and multivisceral (n = 11). Patients who still 
had good liver function received intestine only. Those 
who had inborn and/or TPN-related hepatic dysfunction 
received liver and intestine. Abdominal multivisceral 
grafts were reserved for patients who had extensive ab-
normalities of the gastrointestinal tract caused by ab-
sorptive, motility, or vascular disorders. The principles 
and various modifications of the three generic proce-
dures have been described e1sewhere.9,22-24,26-29 In all 
three recipient cohorts, some of the grafts contained a 
segment of large bowel, whereas others did not. Use of 
the colon was prompted by the high postoperative sto-
mal output and frequent readmissions for treatment of 
dehydration that were frequently observed otherwise.23 
Bone Marrow Transplantation 
Bone marrow cells recovered from the same donor as 
the intestine were infused intravenously into the recipi-
ent during the operation in four recent cases (three pri-
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Figure 1. Three kinds of visceral 
allografts: intestine alone (right), 
liver and intestine (left), and multivis-
ceral (middle). The number of pa-
tients receiving each type of graft is 
indicated by "n." Colonic segments 
(shaded) were included in 29 recipi-
ents scattered through the three co-
horts. IVC: inferior vena cava; PV: 
portal vein; HA: hepatic artery; SMA: 
superior mesenteric artery; SMV: 
superior mesenteric· vein; SA: 
splenic artery; LGA: left gastriC ar-
tery. 
mary and one retransplantation). The rationale and 
methods of simultaneous bone marrow infusion in solid 
organ transplantation have been reported elsewhere.30- 32 
In brief, bone marrow cells were isolated from the thora-
columbar vertebrae of the donor and suspended in 200 
mL of Dulbecco's Modified Eagle Medium (Gibco, 
Grand Island, NY) at a concentration of 6 X 108 cells/kg 
body weight. The infusions were given over 20 minutes, 
2 to 12 hours after revascularization of the intestinal 
graft. 
Postoperative Management 
Immunosuppression was achieved with tacrolimus 
and low-dose steroids, to which prostaglandin EJ was 
added briefly during the early postoperative period. Ad-
justment of tacrolimus dose and/or supplemental pred-
nisone, OKT3, and azathioprine were given for episodes 
of rejection or for tacrolimus-related adverse effects, as 
previously described.22,27,33 In a few cases, azathioprine 
was given as a third drug from the outset. Depression of 
white blood cell count «5000) was treated with 3 to 5 
/.lg/kg granulocyte colony-stimulating factor (Neupogen, 
Amgen, Thousand Oaks, CA). The complex infectious 
disease and nutritional management was as described 
elsewhere.22,27,33,34 
Sampling Protocols 
Rejection Surveillance 
Histopathologic study of endoscope-guided biopsies 
was done twice weekly until hospital discharge, The clin-
Vol. 222.No. 3 
ical diagnosis of rejection was not accepted unless con-
firmed histopathologically by criteria described else-
where.22,35 More than 1440 intestinal biopsy specimens 
have been examined by a single pathologist (R.G.L.). 
Graft-Versus-Host Disease Surveillance 
Suspicious skin lesions were biopsied and studied by 
routine histology, immunohistologic staining for donor-
specific HLA antigens, and in situ hybridization tech-
nique using the Y -chromosome-specific probe, as de-
scribed elsewhere. 12,36,37 
Cytokines 
Plasma samples collected serially from patients who 
did not receive colon (n = 9) and from patients receiving 
colon segments (n = 7) were stored (-70 C) and analyzed 
for tumor necrosis factorA, interleukin-l (3, and interleu-
kin-6 by the enzyme-linked immunosorbent assay 
method (R&D Systems, Minneapolis, MN). 
Chimerism 
Donor leukocyte chimerism was followed before and 
after intestinal transplantation in four patients who also 
were given perioperative bone marrow and in nonmar-
row control recipients of the same kinds of allografts. 
Leukocytes circulating in the recipient peripheral venous 
blood were identified as donor with donor-specific anti-
HLA class I monoclonal antibodies and by fluorescent-
activated cell sort analysis. 3D The results were confirmed 
using probes directed against HLA class II chromosomes 
by polymerase chain reaction (peR) and by in situ hy-
bridization technique with Y-chromosome-specific 
probe. 
Statistics 
Figures are expressed as the mean plus or minus the 
standard deviation of the mean. Differences in group 
means were tested using the one-way analysis of vari-
ance, and differences in proportions were examined us-
ing Pearson's chi square test. Patient and graft survival 
curves were generated using the life table method and 
were compared between the groups using the log-rank 
(Mantel-Cox) test. To analyze the risk factors for mor-
bidity, graft loss, and mortality, Cox's proportional haz-
ards model was used. 
RESULTS 
Cases Without Bone Marrow 
Patient Survival 
All but 1 of the 63 patients have a potential follow-up 
of at least 1 year (range, 1 to 5 years) (Fig. 2). Thirty-two 
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Figure 2. Actuarial patient and primary graft survival of the first 63 recipi-
ents of the procedures depicted in Figure 1. 
are still alive. There was no survival difference with the 
three kinds of operations (Fig. 3) or between the pediatric 
and adult age groups. Twenty-eight of these 32 surviving 
patients still bear their primary allografts, all of which 
function. The other four patients were returned to hy-
peralimentation after graft enterectomy, and one patient 
later underwent successful retransplantation. 
Graft Survival and Function 
All of the four patients returned to chronic intrave-
nous nutrition were in the intestine-alone group (Fig. 4). 
Thus, although a slightly better early patient survival 
(83% at I year) (Fig. 3) was obtained after the intestine-
alone procedure (not significant), this operation suc-
ceeded in restoring alimentary function at the lowest rate 
at all follow-up times after 9 months. The poor survival 
of patients in the intestine-alone group compared with 
that of patients who underwent other operations is 
shown in Figure 5. The results were similar in adults and 
children. 
Successfully treated patients had gratifying rehabilita-
tion_ Although absorption was never completely normal, 
27 of the 28 patients still bearing their original grafts are 
free of intravenous support, and some even have had to 
go on obesity-control diets. Several of the patients take 
special dietary precautions to prevent diarrhea or dys-
motility symptoms. Only one patient requires intermit-
tent nighttime intravenous supplementation. 
Cause of Failure 
Thirty-five (55.6%) of the 63 primary grafts were lost 
by recipient death or as the result of their surgical re-
moval followed by an immediate attempted retransplan-
tation (n = 4) or return to hyperalimentation (n = 4). 
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Figure 3. Patient survival after the three types of allografts shown in Fig· 
ure 1. 
The principal reasons for the primary graft losses are 
summarized schematically in Figure 6. 
In 10 cases, the failures could "be traced back to surgical 
or management errors. Eight of these 10 grafts were func-
tioning at or shortly before the time of their loss. The 
subgroup of technical surgical errors, all in children, in-
cluded intestinal anastomotic leakage, hepatic artery 
thrombosis, biliary anastomotic leakage, and cerebral in-
farction associated with intraoperative cardiac arrest. 
One of the six grievous management errors (Fig. 6) was 
nonrecognition of a pre-existing pneumonia. The graft 
was removed immediately, immunosuppression was 
stopped, and the patient was successfully returned to hy-
peralimentation. Other management errors were over-
dosing or underdosing oftacrolimus or other agents (n = 
4), including a lethal infusion of hypertonic saline. There 
was one failure to diagnose drug noncompliance. 
The exact reason for loss of the other 25 grafts was 
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Figure 4. Primary graft function in the 32 surviving patients after each of 
the three different transplantations. Note that 4 of the 12 intestine·alone 
recipients are alive despite removal of their transplants. 
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Figure 5. Allografi survival with the three different kinds of operations. 
The differences are not statistically significant. 
difficult to pinpoint because of multiple interlocking fac-
tors (Fig. 6). The principal diagnosis was rejection in 
only 6 cases, whereas an infectious complication attrib-
utable to antirejection therapy was the major diagnosis 
in 19. The responsible microorganisms incl uded bacteria 
and fungi (n = 6), but among the viruses, cytomegalovi-
rus (CMV) alone accounted for nearly as many losses (n 
= 5). Moreover, Epstein-Barr virus (EBV) associated B-
cell lymphomas occurred in 12 (19%) of the 63 patients, 
of whom 8 lost their grafts and died of this complication. 
Eleven of the 12 patients who developed the lymphomas 
had been treated with OKT3. 
Retransplantation 
Four patients underwent retransplantation on the 
same day as primary graft removal (two liver-intestine) 
or 1 to 2 months later (two intestine only). They died 47 
days, 57 days, 71 days, and 147 days after the second 
Rejection 
Technical (n = 4) 
and 
Management Errors (n = 6) 
CMV (n=5) 
Lymphoma (n=8) 
Fungal/Bacterial (n=6) 
Rejection (n=6) 
Infection 
Figure 6. Causes of the 35 primary graft losses. 
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Figure 7. Effect on patient survival of donor and recipient CMV+ serol-
ogy. N-N negative donor-negative recipient (26 patients); P-N: positive 
donor-negative recipient (13 patients); N-P: negative donor-positive re-
cipient (17 patients); and poP: positive donor-positive recipient (7 pa-
tients). 
procedure, with the principal diagnoses of rejection (n 
= 2), B-celllymphoma (n = 1), and systemic bacterial 
infection (n = 1). In addition, liver retransplantation was 
unsuccessful in a pediatric patient who developed iso-
lated hepatic artery thrombosis 11 days after combined 
intestine and liver transplantation. 
A fifth intestinal retransplantation was performed in 
an intestine-only recipient 11 months after graft enterec-
tomy. This patient, who is alive, also was given bone 
marrow from the second intestine donor (see beloW). 
Risk Factors 
With univariate and multivariate analysis, 6 statisti-
cally significant risk factors for graft loss and/or death 
among 28 variables examined were high FK 506 blood 
levels, prednisone bolus therapy, administration of 
OKT3, length of operation (reflecting the technical 
difficulty of the procedure), CMV plus status of donor 
and recipient, and inclusion of a segment of colon with 
the graft. The first four of these risk factors have often 
been described with transplantation of other organs and 
will not be considered here except to mention their obvi-
ous relation to the infectious complications. The fifth 
and sixth risk factors were more specific to the intestinal 
recipient. 
The CMV effect was pervasive. Serologically negative 
CMV recipients are surviving after 1 to 5 years at a rate 
of62% if their donors were CMV negative, but only at a 
rate of 47% if their donors were CMV positive (Fig. 7). 
An adverse effect on survival also was observed when the 
recipient already was serologically CMV positive at op-
eration. Fifty-four percent survive to date if a CMV -neg-
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ative donor was used, but only 14% with a CMV -positive 
donor (Fig. 7). As recently reported in detail,38 therapy 
that can regularly control this infection in other kinds of 
allograft recipients was only marginally effective in the 
intestinal recipient. Once the clinical diagnosis of CMV 
was made, the predominant target in essentially all cases 
was the intestinal allograft itself. The resulting ulcer-
ations were associated with bacterial translocation. 
Inclusion of a colonic segment in 29 patients was a 
significant risk factor. Significantly better graft survival 
was observed in 34 patients without the colon than with 
it (Fig. 8). Although the negative colon influence was 
more pronounced in adults, it also was identified in the 
pediatric recipients. 
A possible explanation was the postoperative increase 
in plasma tumor necrosis factor-alpha (and by implica-
tion, endotoxemia) in recipients given colon versus the 
lower levels in nine patients whose grafts did not contain 
colon. Interleukin-llevels were barely detectable in both 
cohorts, and interleukin-6 responses were comparable. 
Bone Marrow Augmentation 
Two of the augmentation patients received intestine 
alone, and two were given liver plus intestine (Table 2). 
All were classified as high risk. Patient 1, an intestinal 
retransplant recipient, had a monoclonal B-cell lym-
phoma that had been in remission since discontinuance 
of immunosuppression and removal of his primary graft 
11 months previously. Although the lymphocytotoxic 
cross-match was negative, he had a high antibody index 
(plasma renin activity) before retransplantation and ex-
perienced a severe rejection during the second postoper-
ative week, which was reversed with OKT3. Shortlyaf-
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Figure 8. Survival of 29 primary grafts containing a colon segment versus 
34 grafts not including colon (p < 0.0313). 
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Table 2. INTESTINAL TRANSPLANTATION WITH DONOR BONE MARROW AUGMENTATION 
(6 X 108/KG CELLS IV) WITH ALL RECIPIENTS CURRENTLY HAVING 0.5-2.5% 
CIRCULATING DONOR LEUKOCYTES 
CMV 
Duration of 
Operation Age Operation (hr) Donor Recipient Complications 
Intestine* (retransplantation) 4.3 10 + Rejection (reversible), EBV 
Intestinet 13.2 9.4 + None 
Liver/bowel 15.0 12.8 + None 
Liver /bowelt 29.2 27 + Pancreatitis, gangrene, jejunum 50 cm resected 
EBV = Epstein-Barr virus antigenemia, B-ceillymphoma in remission; CMV = cytomegalovirus. 
* First intestinal transplant in October 1991; graft enterectomy after 2.1 years and return to parenteral hyperalimentation in 11 months because of B-ceillymphoma. 
t Previous liver transplantalion in December 1984; intestine Infarcted by volvulus in March 1994. 
:j: Protein CIS deficiency; complete portal and mesenteric thrombosis. 
terward, EBV reactivation was diagnosed by in situ hy-
bridization for Epstein-Barr early RNA (EBER), which 
showed staining of the intestinal biopsy specimen. The 
diagnosis was confirmed with semiquantitative EBV an-
tigen titer measurement by PCR. The EBV infection re-
solved within 2 weeks after reduction of immunosup-
pression and administration of two doses of gamma-in-
terferon (Actimmune, Genentech, Inc .. San Francisco, 
CA). 
Patient 2 had undergone a liver transplantation in 
1984 and lost his native intestine to a volvulus 10 years 
later. This patient, like the other three, had extensive pre-
vious procedures. Patient 4, whose complete splanchnic 
venous thrombosis was secondary to protein C and S de-
ficiency, required a 27-hour operation. All four recipi-
ents faced the CMV handicap (Table 2). Patients 1, 2, 
and 3 are receiving oral nutrition, and Patients 2 and 3 
are at home after discharge 4 and 5 weeks postopera-
tively. Patient 4 developed severe acute pancreatitis post-
operatively and required resection of a 50-cm gangre-
nous midjejunum graft during the 3rd postoperative 
week. He is still in the intensive care unit. 
Donor cells were easily detected in all four bone mar-
row augmented bowel recipients by either PCR or flow 
cytometry or both (Fig. 9) up to the last sample tested 
(postoperative day 58). In the female child (Patient 65) 
who received a male allograft, the presence of donor cells 
was confirmed by fluorescent in situ hybridization for 
the Y chromosome. As expected, very low levels (by 
peR only) of donor cell chimerism were detected in the 
peripheral blood of three of the four nonaugmented con-
trol patients for up to 16 weeks after transplantation. 
No evidence of GVHD was found in any of the four 
recipients who were given bone marrow cells. 
DISCUSSION 
The three procedures used in this clinical series are 
products of the post -WorId War II renaissance of surgical 
research laboratories: The intestine-alone operation was 
essentially the same as developed in dogs and described 
to the American Surgical Association 36 years ago by Lil-
lehei et a1.39 The multivisceral procedure and the liver-
intestine variant first used by Grant et a1. 15 are derived 
from an experimental canine operation reported in 
1960.3,40 All three operations are interrelated, because 
the liver, pancreas, and intestine-whether allograft or 
host-can each influence the immunologic environment 
and metabolic nLlllction of the others.9 
With only one exception, the first 63 patients treated 
with these difficult operations have potential follow-ups 
of 1 to 5 years. Thirty-two are still alive. In our earlier 
reports comparing the different operations, the most en-
couraging results were with the intestine alone.22,23 This 
advantage lessened with time,27 so that by 2 years, there 
was no longer a significant difference between the three 
cohorts, and the graft survival after the intestine-alone 
operation turned out to be inferior. Yet, one of these pa-
tients with a failed graft has now had successful re-
transplantation after graft enterectomy and 11 months 
of intervening intravenous nutrition and recovery from 
a B-celllymphoma. The strategy of interval support has 
not yielded great dividends, but it is expected to. Because 
a "rest period" is not an option for patients with failed 
complex grafts that contain liver, we have never per-
formed multivisceral or liver-intestine procedures in pa-
tients who need only the intestine. 
Despite the numerous gratifying successes generated 
by this experience, we self-imposed a moratorium on fur-
ther case accrual throughout most of 1994. The decision 
was made because we had been unable, despite much ex-
perience, to reduce the previously described mortality 
rate, difficulty of postoperative management, and need 
for excessive hospitalization. 22,23,27,41-43 The problems 
were no different in principle than those encountered 
with recipients of other transplanted organs and largely 
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Figure 9. Detection of donor cells in the peripheral blood on bone mar-
row-augmented small-bowel recipient (Patient 1, Table 2) by fluores-
cence·activated cell sorter analysis. Staining with (A) isotype control 
(lgG1), (8) recipient-specific antibody (HLA-B7), and donor specific anti-
body (HLA-B8) on (C) POD 26 and (D) 58, respectively. For analysis, using 
Consort 30 (Becton-Dickinson, Mountain View, CAl acquisition software, 
2 X 10' events were acquired on a FACStarR (Becton-Dickinson). PGE: 
percent gated events. The circulating donor cells are in the right lower 
quadrant of C and D. 
stemmed from the inability to completely control rejec-
tion without resorting to chronic heavy immunosuppres-
sion. 
However, the management difficulties were more fre-
quent and intractable, often leading to infections that 
were the leading cause of death. The interface of rejec-
tion and infection appeared to be closer in these patients 
than after other kinds of organ transplantation. Because 
the bowel wall becomes a bacterial sieve when it is dam-
aged by any mechanism, including rejection,22 the spec-
ter of bacterial translocation resulted in the need for 
heavy immunosuppression. Thus, three of the six sig-
nificant risk factors were high FK 506 levels, high-dose 
steroids, and use ofOKT3. A sinister aspect of the infec-
tion problem was the development ofEBV-associated B-
cell lymphomas that have euphemistically been termed 
"lymphoproliferative disorders.,,44 The lymphomas oc-
curred in 12 (19%) ofthe 63 patients and caused 8 deaths. 
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The three additional significant risk factors identified 
against this complex background could be construed to 
suggest (1) avoidance of predictably difficult patients, 
such as those with multiple previous operations, (2) inel-
igibility of CMV + donors and recipients, and (3) omis-
sion of colon from the allograft to reduce the potential 
liability of endotoxemia.4s-47 However, the first two re-
forms would preclude treatment for almost all of the pa-
tients who need it, and the third would ultimately dimin-
ish the quality of postoperative life. Consequently, less 
restrictive strategies are being evaluated, to which intes-
tinal transplant research has provided seminal clues, into 
the generic mechanisms of graft acceptance. 
In 1990, it was demonstrated in established rae and 
human8-1O intestinal and multivisceral allografts that the 
intestine had changed into a genetic composite after sur-
gery. The epithelial and vascular endothelial compo-
nents remained donor phenotype, but the leukocyte sub-
strate of the lamina propria and elsewhere became re-
populated with recipient cells. It had been known that 
this transformation occurred with the liver,48,49 and it 
was suspected and subsequently proven that the same 
transformation occurred in all established allografts, re-
gardless of the organ. 12,50 The natural question was the 
fate of the replaced donor leukocytes of the graft. The 
answer was that, like events after any kind of trans plan-
tation, the intestinal leukocytes migrated from the allo-
graft and in successful cases established residence 
throughout the recipient. We have postulated that these 
events are the seminal basis of allograft accep-
tance. II ,12,36,37,SI The mutually canceling effect of the co-
existing leukocyte populations (donor and recipient) ex-
plained the freedom from GVHD of the intestinal as well 
as liver recipients. 12 
Although the intestine is a rich source of these migra-
tory white cells, our laboratory studies in rats52 and the 
historic contributions of Monaco et al.S3 ,54 have shown 
that intestinal leukocytes have inferior tolerogenic qual-
ities compared with bone marrow cells. In addition, the 
lineage profile of the migratory intestinal cells were pre-
disposed to GVHD,55-57 a complication never caused in 
the rat models by migratory donor hepatic leukocytes or 
suspensions of bone marrow cells. 52 
To exploit the tolerogenicity and safety of donor bone 
marrow leukocytes, we began a trial 21h years ago of do-
nor leukocyte augmentation with these cells.30-32 In the 
first 100 kidney, liver, heart, or lung recipients, no ad-
verse effects, including GVHD, and considerable benefit 
were observed. Intestinal recipients were excluded from 
the trial during the first 2 years because of concern that 
the extra load of bone marrow leukocytes might cause 
GVHD. Eventually, the favorable experience with the 
other organs prompted extension of the bone marrow 
strategy to intestinal recipients, using the same FK 506-
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steroid immunosuppression as before. The first four in-
testinal recipients treated in this way are alive after 2 to 3 
postoperative months. Donor cells account for approxi-
mately 1 % to 2.5% oftheir circulating mononuclear cells. 
There has been no evidence ofGVHD. 
Aside from this direct therapeutic application, other 
implications of the recently evolved two-way paradigm 
of transplantation 11.12.36.37,51,58 are relevant in assessing 
the intestinal transplant experience. First, the unusual 
infectivity ofCMV is not enigmatic. Because this virus is 
lymphotropic and contained in the migratory cells, it is 
not hard to envision its massive and efficient inoculation 
in either direction (graft to host or vice versa), propor-
tional to the magnitude of cell migration that begins 
within a few minutes after graft revascularization. 
Second, the etiology, prevention, and management of 
the EBV -associated B-celllymphomas that have plagued 
efforts at intestinal transplantation also become more 
understandable. Because of the now obsolete belief that 
intestinal grafts should be T-cell (or pan-leukocyte) de-
pleted to avoid GVHD,4,6.59-63 most of the bowel donors 
before 1990 were treated before organ procurement with 
antilymphoid preparations, or the allografts were irradi-
ated.13.1S.16.64.65 Most of the patients who survived the op-
eration developed B-cell lymphomas of recipient origin. 
The lymphomas were similar to those associated with ov-
erimmunosuppression in recipients of other organs,66.67 
especially after the T-cell-directed agents cyclosporine 
and68,69 FK 50670 became available. 
In a series of studies/1 Klein delineated the cellular 
and molecular mechanisms by which these iatrogenic in-
terventions or inherited immunodeficiency diseases al-
Iowan inherently self-limited EBV infection to proceed 
to a malignancy. In essence, surveillance of potentially 
neoplastic virus-infected B cells depends on the intact T-
cell system that the various procedures used in transplan-
tation disarm in the donor or recipient leukocyte popu-
lations, or both. Suspicion that this was the reason for B-
cell lymphomas in our first multi visceral recipients 
caused us more than 6 years ago to recommend against 
either donor or allograft conditioning.9•72 When B-cell 
lymphomas develop in organ recipients, restoration of 
T-cell surveillance over EBV (whose antigenicity is ex-
pressed during replication71 ) can be accomplished by 
lightening immunosuppression,68 but at the risk of rejec-
tion. 
Bone marrow recipients who are cytoablated (with to-
tal body irradiation or drugs) and given T-cell-depleted 
allografts have an increased incidence of B-celllympho-
mas. These are of donor (not recipient) origin, and the 
option of reducing maintenance immunosuppression 
usually is not available. However, Papadopoulos et al.73 
reported a regression ofthese donor phenotype lympho-
mas by infusing peripheral blood cytotoxic T lympho-
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cytes collected from the original marrow donor. This 
mimics the therapeutic effect achieved in organ recipi-
ents by lightening immunosuppression and allowing re-
cipient T-cell stlrveillance. Predictably, the penalty of 
such treatment in the bone marrow recipients was 
GVHD. 
All of the B-celllymphomas reported in intestinal re-
cipients have been of recipient origin. It is possible to use 
immunotherapy in such patients to treat tumors of this 
kind that fail to respond to reduction immunosuppres-
sion. Unaltered recipient buffy coat or bone marrow 
could be collected preoperatively and stored for such an 
exigency, to be used as a last resort. 
A better understanding of the pathogenesis of B-cell 
lymphomas and other problems of intestinal transplan-
tation is the first step to solving them, particularly if com-
plications are of a unifying etiology. However, progress 
will depend on obtaining stable graft acceptance more 
quickly and completely, thereby decreasing the harm 
caused by high-dose chronic immunosuppression. The 
administration of adjuvant donor bone marrow has this 
objective. Although there is a solid experimental base for 
this approach, its clinical value is unproven. 
Even if the bone marrow initiative is effective, these 
often difficult operations will not be made easier to per-
form. Nevertheless, intestinal transplantation seems to 
us at least as far along as liver transplantation was little 
more than 12 years ago or even kidney transplantation 
in the early 1970s. 
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Discussion 
DR. RONALD W. BUSUTTIL (Los Angeles, California): I 
would like to congratulate Dr. Starzl on his presentation and 
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thank him for providing me with the manuscript. This paper 
is truly a "must" read for all of you who have any interest in 
transplantation. The material described is detailed, it is forth-
right, and it is very timely. 
But as I see it, the real value of this paper lies in the fact that 
it is truly the only series of human intestinal grafts that have 
been studied and scrutinized so closely. Some of us in this room 
have a handful of cases each, but none of us have the extensive 
experience of Dr. Starzl's group, which allows them to advance 
this discipline in truly a scholarly manner. 
The Pittsburgh group has systematically developed not only 
the techniques and protocols for experimental and clinical in-
testinal transplantation, but has also provided us with the sci-
ence to support its cautious application to the clinical setting. 
A few examples of such advances include: 
1. A description and a refinement to both the donor and re-
cipient operations for intestinal transplantation, with a 
view of the indications on whether to use the intestine 
alone, the liver plus the intestine, or a multivisceral graft. 
2. Conducting seminal experiments on the use of F-K 
506 in immunosuppression for this group of patients. 
3. Showing depletion of the immunocytes in the intestinal 
graft is not necessary and indeed may be deleterious to 
graft function. 
In this paper are the important observations that retention of 
the ileocecal valve and colon to decrease the intractable diar-
rhea after small bowel transplantation is counterproductive 
and that cytomegalovirus (CMV) disease, particularly when it 
is primary, is disastrous for graft survival. 
Finally, the finding of a 19% incidence of B-celllymphoma 
with a 67% mortality is ominous. 
These findings are extremely important. However, they leave 
many unanswered questions. 
First, why is CMV prophylaxis ineffective in intestinal trans-
plantation while it is extremely effective in liver allografts? In 
our own series at UCLA, we have eradicated CMV disease by 
giving intravenous gancicIovir for 100 days post-transplant, 
even in the sinister combination ofCMV-positive donors and 
CMV-negative recipients. Is it the increased immunosuppres-
sion used in intestinal grafting or are other factors involved? 
Second, is it possible that CMV alters the lymphocyte 
trafficking that is seen after intestinal transplantation and thus 
through this mechanism makes the grafts more susceptible to 
rejection? Is the problem with the retention of the colon a me-
chanical one? Is it bacterial overgrowth? Is it rejection? Or is it 
the site where CMV becomes manifested? You suggested that 
increased levels of tumor necrosis factor-alpha and its relation-
ship to increased endotoxin may be the cause for this problem 
in these patients. If this is the case, have you considered using 
anti-tumor necrosis factor antibody in these patients? 
The incidence of B-celilymphoma is a real problem. What 
strategies are you currently using for prevention of treatment? 
It seems improbable to completely avoid OKT-3 usage in this 
group of patients. 
You have used bone marrow transplantation to augment 
four of these patients in your more recent series, what do you 
think the role of this added procedure is in intestinal transplan-
tation? 
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Finally, I would like to echo what Dr. Starzl said, that al-
though the results of intestinal transplantation are not very en-
couraging at the present time, they are where we were about 15 
years ago with liver allografting. 
I think it is extremely encouraging that 27 of the 28 patients 
who retain their original grafts are not dependent on intrave-
nous nutritional support. I think this is truly an outstanding 
result and I congratulate the authors on this very fine piece of 
work. 
DR. ALAN LANGANAS (Omaha, Nebraska): At the Univer-
sity of Nebraska, we have performed 21 intestinal transplants 
to date. Without the seminal work by the University of Pitts-
burgh, these efforts would have not been possible. 
My questions primarily relate to those that were alluded to 
by Dr. Busuttil, and in particular, viral infections. 
We have observed similar events that you have seen with Ep-
stein-Barr virus and cytomegalovirus (CMV)-related infec-
tions. What is not clear to me is why the CMV and Epstein-
Barr virus not only are more virulent but appear to be more 
pernicious after intestinal transplantation. I would be inter-
ested in hearing why you think this organ is different than many 
others used in transplantation. As we all know, for liver 
transplant recipients, if you have a CMV-positive donor organ 
placed into CMV-negative recipient, you will see an 80% inci-
dence ofCMV-related disease, but this is an unusual and infre-
quent cause of graft loss or death. 
My second question relates to the use of the bone marrow. 
As you have written about many times, after a liver transplan-
tation recipient passes through the initial turmoil of the first 
few weeks or months after transplantation, often they enter a 
quiescent phase in which there appears to be a greater graft ac-
ceptance. You have proposed that cell trafficking of lymphoid 
lineage passes from the liver and settles into distant sites in the 
recipient. In intestinal transplantation, despite the huge lym-
phoid mass of the organ itself, we do not really see this "accom-
modation" ofthe transplanted organ. Why does this not occur, 
and why is donor bone marrow required? 
DR. FRANCIS D. MOORE (Boston, Massachusetts): I, also, 
would like to congratulate Tom Starzl on behalf of all of us for 
his remarkable leadership in this difficult field. And I would like 
to go to a very detailed question. 
He gave some bone marrow cells. I assume those were from 
the same donor. He did not state that clearly, but I assume they 
were. Did those patients have any different incidence of the B-
cell lymphoma? Because that is a most remarkable finding in 
this series of cases. 
DR. S. TODO (Closing Discussion): Thank you very much, 
Dr. Busuttil, Dr. Langanas, and Dr. Moore. I would like to take 
the clinical questions. Dr. Starzl will answer questions about 
the bone marrow program and the lymphomas. 
Two of the discussants asked why these patients have such a 
high incidence of infections. This is due partly to the high-level 
maintenance requirements for FK 506, the frequent need for 
OKT-3, and the repeated use of steroid boluses. For the liver 
patient, we keep the FK trough level of whole blood in the 10-
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to 15-ng/mL range. To control rejection in the intestinal recip-
ient, the level often has been kept twice as high. There may be 
other confounding factors with the viral infections which Dr. 
Starzl will discuss, to explain why the enterocyte is the main 
target of the cytomegalovirus (CMV) infections. We use the 
same treatment strategies for CMV prophylaxis, such as 
acyclovir and ganciclovir for 2 to 3 months after transplant, as 
for other kinds of organ recipients. Yet, patients who received 
the CMV-seropositive intestine-containing grafts seemed not 
to be equivalently treatable. Typically, their difficulties sur-
faced after three to four months. 
Regarding the higher tumor necrosis level in the colon recip-
ient, we may be able to use anti-tumor necrosis factor antibody 
to mitigate the harmful consequences, particularly those asso-
ciated with the colon, as Dr. Busuttil showed several years ago 
in experimental transplant models. 
DR. THOMAS E. STARZL (Closing Discussion): Dr. Todo is 
such a fine scientist that he does not like to speculate and is 
inclined to leave that to his junior partner. 
First, one could speculate about the unusual penetrance of 
cytomegalovirus (CMV). This is a Iymphotropic virus. It is 
hard to think of a more spectacular way to disseminate a CMV 
infection than by the ubiquitous migration of the cells that 
carry the virus. Relevant to Dr. Moore's comment, the domi-
nant cell population migrating from the intestine is lympho-
cytic. 
This is the reason why the large number of white cells mi-
grating from the intestinal graft fails to induce the kind of rapid 
graft acceptance that Dr. Langanas has pointed out is common 
after liver transplantation. This has been demonstrated in re-
cent rat study (M urase et al. Transplantation 1995; 60: 158-
171). Among the parenchymal and secondary lymphoid or-
gans, the liver and bone marrow were the most tolerogenic and 
least likely to cause graft-versus-host disease. The migratory 
leukocytes from these two sources had a heavy representation 
of cells of myeloid lineage with a much smaller lymphocyte 
component-in contrast to the lymphocyte-rich intestine. 
The B-celllymphoma problem also can be considered in the 
lymphocyte context. I would like to suggest a treatment ap-
proach for these intestinal patients which is speculative, but 
which has worked in a mirror image version for bone marrow 
recipients suffering this complication. In essence, the hyperpro-
liferating cells are B lymphocytes in which the Epstein-Barr vi-
rus is contained. Most of us carry this oncogenic virus in our B 
cells, but as George Klein of Stockholm has demonstrated, the 
quiescent virus is nonantigenic. When the virus replicates-
coincident with hyperproliferation of the B lymphocytes-six 
or perhaps as many as eight variants of the virus are expressed. 
All are antigenic except the original one that has been sustain-
ing the virus in the latent state. With replication, competent 
cytotoxic T cells pounce on the antigenic virus and coinciden-
tally destroy the B cells in which they reside. That is why we do 
not all have B-celilymphomas. 
How to exploit that information has been clear in whole or-
gan recipients. All that is necessary is to reduce or stop immu-
nosuppression allowing recovery of the host cytotoxic T lym-
phocytes which then carry out their normal B-lymphocyte sur-
veillance. The consequence is that the tumors melt away. In 
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whole organ recipients, these tumors are essentially always of 
host origin. 
In contrast, the B-celllymphomas after conventional bone mar-
row transplantation (after recipient cytoablation) rise from donor, 
not recipient cells. The strategy of reducing immunosuppression is 
not feasible. However, a spectacular regression of the donor-type 
lymphomas has been reported in bone marrow recipients after in-
fusion offresh cytotoxic T lymphocytes obtained from the original 
donor (Papadopoulos et al. New EngJ Med 1994; 330:1185-1191). 
The principal risk is graft-versus-host disease. 
An analogous approach should be feasible in the high-risk 
Ann. Surg .• September 1995 
intestinal recipient whose immunologic surveillance fails to re-
cover despite stopping immunosuppression. This will require 
the simple precaution of storing and preserving either recipient 
bone marrow or blood buffy coat preoperatively so that the cells 
can be infused later, in the event of B-ceillymphoma develop-
ment. Here, the principal risk will be rejection. In his analysis of 
a paper that I gave to this organization in 1989, Francis Moore 
pointed out that if we understood the pathogenesis of the post-
transplant lymphomas in intestinal recipients, we would be 
able to rationally treat them. I believe that my suggestion will 
prove the wisdom of Dr. Moore's prophecy. 
